Investigation Report on China's Entecavir Market, 2018-2022

In China, more than 100 billion people are chronically infected with hepatitis B virus (HBV), of which 20 million to 30 million have chronic hepatitis B. It is estimated that every year, more than 500,000 people in China die of the liver damage or liver cancer caused by chronic hepatitis B, which leads to losses of over CNY 100 billion.

Developed by Bristol-Myers Squibb, Entecavir is a nucleoside analogue taken by mouth. In Mar. 2005, Entecavir was approved by the FDA. Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir was launched in China at the beginning of 2006 after being approved by the China Food and Drug Administration (CFDA) at the end of 2005. Later, Chinese pharmaceutical companies launched generic Entecavir successively, which drove the growth of the market.

The market research, the annual sales value of Entecavir increased from over CNY 30 million in 2006 to CNY 2.03 billion in 2016, and decreased slightly in 2017. Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir still dominates the market. Its market share by sales value reached about 40% in 2017 but is shrinking as impacted by China-made generic drugs.

Entecavir has better and faster antiviral effect and see less side effects and drug resistance than traditional nucleoside analogs. Having a high genetic barrier to resistance, it is a powerful and long-acting HBV inhibitor for early monotherapy. As the demand for new anti-HBV drugs is far from being met, China's Entecavir market is promising with rising sales value in the coming years.

Email alert

Market Insights

The global frozen processed food market will be valued at US$69.11 billion by 2021 as compared to US$57.50 billion in 2014, displaying a modest CAGR of 2.7% in terms of profit. However, the global frozen processed foods ma...

As per a study piloted by the University of California, the merchandises contrived in China are linked with substantially greater carbon dioxide emanations as compared to the similar products manufactured in another place....

The global market for smart healthcare is expected to record an inspiring 25.0% CAGR between 2016 and 2020. The massively growing acceptance of healthcare wearables amongst buyers is one of the main reasons projected to bo...

The crop protection chemicals market is likely to grow at a CAGR of 5.15% to touch US$ 70.57 billion by 2021. The market propelled by the intensifying requirement for food security for the budding population, innovation in...

Thermoplastic polyolefin (TPO) is extensively used in manufacturing industries like automotive, home appliances, footwear, medical, and building and construction. Owing to its outstanding UV-resistant and durability proper...